281 related articles for article (PubMed ID: 7873659)
1. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
Lewis MR; Raubitschek A; Shively JE
Bioconjug Chem; 1994; 5(6):565-76. PubMed ID: 7873659
[TBL] [Abstract][Full Text] [Related]
2. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions.
Lewis MR; Shively JE
Bioconjug Chem; 1998; 9(1):72-86. PubMed ID: 9460549
[TBL] [Abstract][Full Text] [Related]
3. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
Kukis DL; DeNardo SJ; DeNardo GL; O'Donnell RT; Meares CF
J Nucl Med; 1998 Dec; 39(12):2105-10. PubMed ID: 9867151
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
[TBL] [Abstract][Full Text] [Related]
5. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
6. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies.
Wilbur DS; Chyan MK; Hamlin DK; Kegley BB; Nilsson R; Sandberg BE; Brechbiel M
Bioconjug Chem; 2002; 13(5):1079-92. PubMed ID: 12236790
[TBL] [Abstract][Full Text] [Related]
7. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA.
Lewis MR; Kao JY; Anderson AL; Shively JE; Raubitschek A
Bioconjug Chem; 2001; 12(2):320-4. PubMed ID: 11312695
[TBL] [Abstract][Full Text] [Related]
8. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
[TBL] [Abstract][Full Text] [Related]
9. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.
Li M; Meares CF; Zhong GR; Miers L; Xiong CY; DeNardo SJ
Bioconjug Chem; 1994; 5(2):101-4. PubMed ID: 8031871
[TBL] [Abstract][Full Text] [Related]
10. Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.
Cooper MS; Ma MT; Sunassee K; Shaw KP; Williams JD; Paul RL; Donnelly PS; Blower PJ
Bioconjug Chem; 2012 May; 23(5):1029-39. PubMed ID: 22471317
[TBL] [Abstract][Full Text] [Related]
11. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
Lu SX; Takach EJ; Solomon M; Zhu Q; Law SJ; Hsieh FY
J Pharm Sci; 2005 Apr; 94(4):788-97. PubMed ID: 15729708
[TBL] [Abstract][Full Text] [Related]
12. Labeling of monoclonal antibody conjugates with 90Y.
Motta-Hennessy C; Sharkey RM; Goldenberg DM
Int J Rad Appl Instrum A; 1991; 42(5):421-6. PubMed ID: 1646187
[TBL] [Abstract][Full Text] [Related]
13. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
[TBL] [Abstract][Full Text] [Related]
14. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates.
Kukis DL; Diril H; Greiner DP; DeNardo SJ; DeNardo GL; Salako QA; Meares CF
Cancer; 1994 Feb; 73(3 Suppl):779-86. PubMed ID: 8306260
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.
Chappell LL; Ma D; Milenic DE; Garmestani K; Venditto V; Beitzel MP; Brechbiel MW
Nucl Med Biol; 2003 Aug; 30(6):581-95. PubMed ID: 12900284
[TBL] [Abstract][Full Text] [Related]
17. Investigations of N-linked macrocycles for 111In and 90Y labeling of proteins.
Wu C; Virzi F; Hnatowich DJ
Int J Rad Appl Instrum B; 1992 Feb; 19(2):239-44. PubMed ID: 1601676
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy.
Pnwar P; Iznaga-Escobar N; Mishra P; Srivastava V; Sharma RK; Chandra R; Mishra AK
Cancer Biol Ther; 2005 Aug; 4(8):854-60. PubMed ID: 16082184
[TBL] [Abstract][Full Text] [Related]
19. High-specific-activity 111In-labeled anticarcinoembryonic antigen monoclonal antibody: improved method for the synthesis of diethylenetriaminepentaacetic acid conjugates.
Paxton RJ; Jakowatz JG; Beatty JD; Beatty BG; Vlahos WG; Williams LE; Clark BR; Shively JE
Cancer Res; 1985 Nov; 45(11 Pt 2):5694-9. PubMed ID: 4053042
[TBL] [Abstract][Full Text] [Related]
20. Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
Li M; Meares CF; Salako Q; Kukis DL; Zhong GR; Miers L; DeNardo SJ
Cancer Res; 1995 Dec; 55(23 Suppl):5726s-5728s. PubMed ID: 7493335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
